UKRG Handbook


CONTENTS

  1)  INTRODUCTION
2) USEFUL CONTACT POINTS
    2.1)  USEFUL CONTACT POINTS - UK  RADIOPHARMACY  GROUP  MEMBERS
    2.2)  USEFUL CONTACT POINTS, MANUFACTURERS AND SUPPLIERS
  2.2.1)  Radiopharmaceuticals
2.2.2) PET and Krypton ML Manufacturers
2.2.3) Radiochemicals
2.2.4) Medical Quality Argon (zero grade)
2.2.5) Chemical and Laboratory Equipment
2.2.6) Radionuclide  Dose Calibrators, Radiochromatographic Scanners, Gamma Counters, Phosphor Imagers and Instant Imagers
2.2.7) Radiopharmacy Equipment
2.2.8) Isolators for Radiopharmacy
2.2.9) Waste Disposal
2.2.10) Clean Room Accessories
3) PHARMACOPOEIAL MONOGRAPHS.
BP and E.P
USP
BP only
4) RADIOPHARMACEUTICALS AVAILABLE WITH MARKETING AUTHORISATIONS (OCTOBER 2001)
Schering
Bristol-Myers Squibb
Mallinckrodt (Tyco)
Amersham Health
Immunomedics
5)   IDENTIFICATION TESTS
5.1)  Introduction
5.2)  99mTc 123I Human Serum Albumin by Electrophoresis
5.3)   14C Urea by chromatography
6) RADIOCHEMICAL PURITY SYSTEMS OF RADIOPHARMACEUTICALS
6.1) Thin-layer chromatography of technetium radiopharmaceuticals
6.2) Thin-layer chromatography of other radiopharmaceuticals
    6.3) Solid phase extraction cartridge methods    
6.4) 99mTc exametazime extraction method
6.5) HPLC Methods
7) FORMULARY SECTION
       7.A    NON-RADIOACTIVE REAGENTS AND DILUENTS.
7.A.1)  ACD Solution BP Formula A
7.A.2)  Hespan (6% Hetastarch in Normal Saline)
7.A.3)   Tropolone in HEPES/Saline Buffer Injection
7.A.4)  Benzyl Alcohol 1% in Sodium Chloride 0.9% Injection
7A.5) Sodium Chloride 0.58% and Sodium citrate dihydrate 1% injection
7.A.6)  Sodium Perchlorate Injection 20mg/ml
7.A.7) 4.4% Disodium edetate solution equivalent
7.A.8) Adenosine infusion 1mg/ml
7.A.9) Intrinsic Factor (Porcine) 100 mg Capsules
         7B    RADIOPHARMACEUTICALS
7.B.1)   Technetium Labelled Denatured Red Blood Cells
7.B.2)   Technetium In-Vitro Labelling of Red Blood Cells
7.B.3)   Radiopharmaceuticals for Gastric Emptying
7.B.4)   99mTc- (V) - DMSA (Addenbrooke's)
7.B.5)   99mTc-(V) - DMSA  (Birmingham)
7.B.6)   Method for Concentrating 99mTc Generator Eluate (for 99mTc-technegas preparation)
7.B.7)   111In-Indium Labelling of Platelets (using 111In-tropolonate)
7.B.8)  111In-Indium Labelling of White Blood Cells (using 111In-tropolonate and includes lysis of red blood cells)
7.B.9) 111In-Indium Labelling of White Blood Cells (using 111In-tropolonate in plasma)
7.B.10)   Indium - 111 labelled capsules for investigation of colonic transit
7.B.11) Ferrous fumarate solution for iron absorption
7.B.12) Carbon -14 Urea Solution
7.B.13) Carbon-14 Urea Capsules
7.B.14) Radiopharmaceuticals for Protein-loss Enteropathy Studies
7.C RADIOPHARMACEUTICALS DILUENT DIRECTORY
8)   DRUG INTERACTIONS
 
 
 
 
 
 
9)    RADIOPHARMACY AUDIT
10)   ADVERSE REACTIONS AND DEFECTS
10.1) ADVERSE REACTIONS AND SYMPTOMS FOLLOWING ADMINISTRATION.
10.2)  DEFECTIVE PRODUCT REPORTS
10.3)   UNANTICIPATED BIODISTRIBUTION OF RADIOPHARMACEUTICALS
11)   PAEDIATRIC ACTIVITIES OF RADIOPHARMACEUTICALS
12)   BIBLIOGRAPHY AND USEFUL SOURCES OF INFORMATION
12.1) General reading
12.2) Official publications
12.3) Guidelines
12.4) British Standards
 

 

Last updated 04.01.04